Monday, August 10, 2026 opened quietly — the S&P 500 building modestly on last week’s best gain since April — but underneath that calm index-level tape, it was an unusually busy morning for deal-making and clinical-trial catalysts. Three separate acquisitions above $1 billion each sent their target companies soaring by double digits before 10 a.m. Two clinical-stage biotechs posted trial data strong enough to trigger 35%-plus rallies on the same session. And a basket of small, largely unknown rare-earth and critical-mineral names caught a fresh government-spending tailwind. Here are 10 top gainer stocks today — deliberately built around the names beyond the household ones, since that’s where today’s real action was.

Top Gainer Stocks Today — Aug 10, 2026:

1. BWMN — Bowman Consulting Group | ~$42.27 | +55.23% | Volume: 6x Average | Market Cap: ~$1B (Deal Value)

Full Data Snapshot:

The Catalyst: Bowman Consulting, a national engineering, geospatial, and infrastructure program-management firm, announced Monday it has entered a definitive agreement to be acquired by Bernhard Capital Partners, an infrastructure- and services-focused private equity firm, for $43.00 per share in cash. The board unanimously approved the deal, and holders of roughly 15.3% of voting power have already agreed to support it. A 35-day “go-shop” period runs until September 13, 2026, meaning Bowman can still solicit superior competing offers before the deal is locked in. Bowman also reported strong underlying Q2 2026 results the same morning — double-digit growth in net revenue, organic growth, adjusted EBITDA margin, and backlog — though the acquisition news has overwhelmed the operating print. The company’s previously scheduled August 11 earnings call was canceled as a result of the transaction.

2. VREX — Varex Imaging Corporation | Up ~47% Premarket | Market Cap Pre-Deal: ~$578M

Full Data Snapshot:

The Catalyst: Teledyne Technologies agreed Monday to acquire Varex Imaging — the world’s only commercially ready independent photon-counting CT detector supplier — in an all-cash deal worth approximately $1.1 billion, or $18.90 per share. The deal gives Teledyne a component supplier that sells into GE HealthCare, Siemens Healthineers, and Philips’ imaging supply chains, and would be the largest single addition to Teledyne’s Digital Imaging segment since its 2021 FLIR Systems acquisition. Varex had earnings scheduled for after Monday’s close, but the acquisition news overtook that report entirely. The transaction has been approved by both boards and remains subject to an HSR antitrust filing, likely international regulatory clearances, and Varex shareholder approval, with no closing date yet specified.

3. HZO — MarineMax Inc | $51.94 | +45.5% | New 52-Week High | Deal Value: ~$1.5B

Full Data Snapshot:

The Catalyst: MarineMax, the world’s largest recreational boat and yacht retailer, jumped 45.5% after entering a definitive agreement to be acquired by Safe Harbor Marinas, an affiliate of Blackstone, for $53.00 per share in cash, unanimously approved by the board. The all-cash structure removes floating-exchange-ratio risk for shareholders, and the deal takes MarineMax private, ending its run as a public retail proxy for the boating and marine leisure economy. MarineMax is up 116% year-to-date even before today’s jump, though the stock has still badly lagged a simple buy-and-hold five years ago given how far it fell during the intervening downturn.

4. SLN — Silence Therapeutics plc | $16.35 | +36.82% | New 52-Week High | Volume: Heavy

Full Data Snapshot:

The Catalyst: London-based Silence Therapeutics, a clinical-stage siRNA (short interfering RNA) biotech, reported positive topline results Monday morning from its Phase 2 SANRECO trial of divesiran in polycythemia vera (PV) — a rare blood disorder causing dangerous overproduction of red blood cells. In the 36-week, randomized, placebo-controlled trial of 48 phlebotomy-dependent PV patients, 88% of divesiran-treated patients achieved the primary endpoint (freedom from phlebotomy while maintaining safe hematocrit levels) versus just 19% on placebo — a statistically overwhelming result (p<0.0001). Chief Medical Officer Curtis Rambaran called it the company’s “best-case outcome,” noting the drug showed equally robust effects whether dosed every six or twelve weeks. Shares had already climbed from around $10.49 in mid-July to nearly $12 by August 7 in anticipation of the data, then gapped sharply higher on the actual readout.

5. ABCL — AbCellera Biologics | ~$9.39–$9.75 | +35–36% | New 52-Week High | Market Cap: ~$2.12B

Full Data Snapshot:

The Catalyst: AbCellera extended its Friday breakout after reporting that a mid-stage trial of ABCL635, its experimental non-hormonal treatment for menopause-related hot flashes, significantly reduced both the frequency and severity of moderate-to-severe hot flashes at four weeks versus placebo after a single dose. CEO Carl Hansen previously described the data as “beyond even the most aggressive upside scenario we had dared to consider.” ABCL635 targets NK3R, the neurokinin 3 receptor involved in body temperature regulation, positioning it as a potential first-in-class option for an estimated 30 million U.S. women with moderate-to-severe vasomotor symptoms. A separate Vertex Pharmaceuticals collaboration, bringing $28 million upfront with Vertex funding R&D through Phase 1, adds a second independent catalyst supporting the stock’s continued strength into a second trading session.

6. ACHR — Archer Aviation Inc | $6.49 | +16.29% | Volume: 61.11M | Market Cap: $4.95B

Full Data Snapshot:

The Catalyst: Archer Aviation is surging after announcing it will acquire Boeing’s Wisk Aero, SkyGrid, and Insitu subsidiaries, with Boeing receiving a nearly 20% equity stake in the combined company. The deal adds a profitable $200 million-plus annual revenue defense business operating in 35 countries, along with validated autonomous VTOL technology and Boeing’s engineering pedigree — transforming Archer’s narrative from “air taxi startup” to “defense-backed autonomous aviation platform” in a single announcement. The company is also the Official Air Taxi Provider for the LA28 Olympic Games and recently cleared Phase 3 of FAA Type Certification, adding operational milestones to the deal-driven momentum. Archer remains a pre-revenue story by traditional metrics — Q1 2026 revenue was just $1.6 million against a net loss of $217.7 million — meaning the stock continues to trade on strategic milestones rather than near-term financials.

7. Critical Minerals Basket — CRML, UAMY, USAR, FEAM | Sector-Wide Rally on Federal Funding

Full Data Snapshot (Individual Movers):

The Catalyst: The White House announced late Friday more than $2 billion in new mining and mining-related investments, plus over $180 million for mining schools and workforce development — a policy tailwind that lifted the entire critical-minerals and rare-earth complex Monday morning. Critical Metals (CRML) has been an especially high-beta name in the group:

the stock remains roughly 80% below its 52-week high of $32.15 and continues trading as a leveraged proxy for Western rare-earth supply-chain sentiment even without company-specific news on a given day. USA Rare Earth (USAR) enters the week fresh off completing its previously announced merger with Texas Mineral Resources on August 7, adding a corporate-structure catalyst on top of the sector tailwind, though Roth Capital recently trimmed its price target to $30 from $40 even while maintaining a Buy rating, and CNBC has flagged unusually heavy, directionally bearish put volume in the name — a reminder that not all the smart money is chasing this rally.

8. LXU — LSB Industries | Upgraded to Outperform | RBC Capital Price Target: $13

The Catalyst: LSB Industries, a nitrogen fertilizer and chemical producer, was upgraded to Outperform from Market Perform at RBC Capital Monday, with the firm setting a $13 price target. RBC’s thesis centers on elevated nitrogen prices supporting strong free cash flow generation for LSB in 2026 and 2027 — the firm projects a 10% FCF yield in 2026, expanding to 13% in 2027 — alongside improving operational execution. This is a smaller, more contained move than the M&A and biotech names above, but it’s a legitimate analyst-driven catalyst in a name that trades well outside the mega-cap spotlight, and nitrogen/fertilizer pricing has been one of the quieter commodity stories of 2026.

9. TH — Target Hospitality Corp | Q2 Beat, Guidance Raised, Massive Contract Win

Full Data Snapshot:

The Catalyst: Target Hospitality, which provides specialty workforce accommodations and hospitality services, reported Q2 revenue of $86 million against a $79.3 million consensus, and raised full-year 2026 revenue guidance meaningfully to $410–$420 million from a prior $370–$380 million range. The company also disclosed more than $1.4 billion in multi-year contract awards representing over 9,000 beds within its Workforce Hospitality Solutions segment — a substantial forward-revenue signal for a company of this size, tying directly into continued growth in energy, infrastructure, and industrial workforce housing demand.

10. Storage & Enterprise Hardware — HPE, NTAP | Morgan Stanley Flips Bullish on “Chipflation”

The Catalyst: Morgan Stanley made a cluster of ratings changes across enterprise storage and hardware Monday: Hewlett Packard Enterprise (HPE) and Pure Storage were both upgraded to Overweight, NetApp (NTAP) was upgraded to Equal Weight, while Teradata (TDC) was downgraded to Equal Weight. The core thesis, in the firm’s own framing, is that “chipflation” — rising memory and component costs — is accelerating rather than delaying enterprise server and storage spending, as buyers rush to lock in capacity and pricing ahead of further cost increases, a reversal from the more cautious view Morgan Stanley held as recently as last November. The firm also raised its overall IT Hardware industry view to In-Line, acknowledging the cycle is maturing but still sees selective stock-level opportunity within it.

The Day’s Dominant Theme: Deal-Making Meets Data-Driven Biotech

Two forces defined Monday’s gainer list:

1. A trio of billion-dollar-plus acquisitions (BWMN, VREX, HZO) hit within hours of each other, each carrying premiums between 58% and 96% — a signal that strategic and private-equity buyers see current valuations across engineering services, medical imaging components, and marine retail as attractive entry points, even with the broader market near record highs.
2. Binary clinical trial catalysts (SLN, ABCL) proved just as powerful as M&A, with both biotechs posting genuine statistical wins that pushed shares to fresh 52-week highs — a reminder that idiosyncratic, company-specific catalysts continue to dominate single-stock action even in a quiet, calm index-level session.

Follow TNN for daily stock market news and financial news today.

Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss. Support and resistance levels cited are technical analysis estimates based on historical price data and do not guarantee future price behaviour. Always complete independent due diligence prior to executing equity trades.

About The Author

Kasia Davis

See author's posts